AI summary by TwinMind
Supplements for Longevity & Their Efficacy | Dr. Peter Attia
Andrew Huberman
2h 30m 41s
Framework for Longevity Approaches
- Four categories of longevity interventions discussed
- Dos/don'ts: exercise (Zone 2 cardio, resistance training), nutrition, genetics
- Calories/glucose/insulin targeting mTOR pathway
- Targeting specific cellular pathways (NAD pathway focus)
- Kitchen sink approach (Brian Johnson-style comprehensive interventions)
- Peter's alternative framework: behavioral essentials vs. exogenous molecules
- Category 1: Essential behaviors (eating, sleeping, moving) - choice is how to do them correctly
- Category 2: Molecules targeting disease processes (Metformin, SGLT2 inhibitors, statins)
- Category 3: Geroprotective molecules targeting aging hallmarks (rapamycin)
Peter's Current Supplement Regimen
- Disease-specific: PCSK9 inhibitor, bempedoic acid, SGLT2 inhibitor
- Geroprotective: Rapamycin 8mg once weekly (with breaks due to aphthous ulcers)
- Other supplements: EPA/DHA fish oil, curcumin, vitamin D (5,000 IU), methyl folate, methyl B12
- Sleep support: magnesium L-threonate, ashwagandha
- Magnesium in three forms: L-threonate, slow-release chloride, oxide
- Probiotics: Pendulum (glucose control, polyphenol, Akkermansia)
- Daily: Element electrolytes, creatine monohydrate 5g, AG1
Andrew's Supplement Regimen
- Core daily: AG1 (1-2 servings), quality fish oil (>1g EPA), vitamin D3 (5,000 IU)
- Testosterone support: Tongkat Ali (lowers SHBG)
- Energy/cognitive: Green tea capsules, yerba mate, creatine monohydrate 10g
- NAD pathway: NMN powder (1,500mg sublingual), occasionally NR
- Sleep support: magnesium threonate, apigenin 50mg, theanine, occasionally inositol 900mg
- Other: methyl B12, Element electrolytes, whey protein
Rapamycin Deep Dive
- Only two interventions extend life across species: caloric restriction and rapamycin
- Peter's dosing: 8mg weekly with breaks due to aphthous ulcers (10% experience this)
- Mechanism: mTOR inhibition, autophagy stimulation, senescent cell suppression
- Upcoming data: Dog aging study (2026), University of San Antonio mammal trials
- Key human study: 2014 everolimus study showed enhanced immune response to flu vaccine in 65+ year olds
- Dosing matters: daily suppresses immunity, weekly pulsing enhances it
Sirtuins and NAD Pathway History
- Original discovery: Matt Kaeberlein's 1999 yeast study showing SIR2 overexpression extends lifespan
- Key finding: Caloric restriction and sirtuin activation are parallel, not connected pathways
- 2004 study proved additivity: CR + sirtuin overexpression = longer lifespan than either alone
- Only one mammalian success: 2012 transgenic mouse overexpressing SIRT6 (10-15% male lifespan extension)
- Resveratrol failure: ITP testing showed no lifespan extension despite theoretical sirtuin activation
NAD Biology and Metabolism
- Present in essentially every cell except possibly red blood cells
- 99% function: co-factor for 500-600 electron shuttle pathways (NAD ⇌ NADH)
- 1% function: substrate consumption by sirtuins for DNA repair
- Tight regulation like glucose and pH - narrow functional band essential for survival
- Age-related decline: skin 60% reduction, brain/blood ~20% reduction over lifetime
- 2015 study: NAD levels decline but NADH levels increase with age
- Real issue: reduced redox potential, not absolute NAD deficiency
NAD Supplementation Options and Bioavailability
- Direct NAD: IV infusion only (oral breaks down in gut)
- Andrew's experience: 10 minutes chest pressure, nausea, cramping, then feeling good
- Cost: $300-1,000 per infusion
- NMN (nicotinamide mononucleotide): Cannot cross cell membrane directly due to phosphate group
- Sublingual or oral administration, phosphate cleaved in gut
- Andrew takes 1,500mg sublingual, observes hair/nail growth acceleration
- NR (nicotinamide riboside): Crosses cell membrane directly
- FDA GRAS status, commercially available
- Claims 25% more effective than NMN milligram-for-milligram
- Mouse studies require 500-1,000mg/kg (50-100g for 100kg human) - economically unfeasible
Clinical Evidence for NAD Supplementation
ITP (Interventions Testing Program) Results
- Gold standard for longevity molecule testing in mice
- NR tested at high doses: NO lifespan extension, NO health span improvement
- Contrast with successful molecules: rapamycin, canagliflozin, acarbose, 17-alpha-estradiol
Human Studies - Mixed Results
- Fatty liver study: No primary endpoint improvement
- Sub-analysis: modest hepatic fat reduction in <27% fat group (statistical not clinical significance)
- Glucose disposal study: minimal improvement in insulin-mediated glucose uptake
- Statistically significant but clinically irrelevant magnitude
Potential Skin Cancer Benefit
- One study showed 60-80% reduction in basal and squamous cell carcinomas
- No effect on melanoma (the deadly skin cancer)
- Mechanistically interesting: skin shows greatest age-related NAD decline
- Requires replication before drawing conclusions
FDA Regulatory Status
- NMN: FDA ruled should not be sold as supplement due to clinical trial designation
- Many companies continue selling despite ruling
- Regulatory limbo similar to N-acetyl cysteine situation
- NR: GRAS status, freely available as supplement
Commercial Considerations
- Peter views NR vs NMN debate as purely commercial positioning
- No meaningful scientific difference between the two
- Cost considerations drive choice more than efficacy differences
- Mouse-equivalent doses would cost ~$300/day in humans
Biological Age Testing Critique
- Peter strongly skeptical of biological age tests
- Key question: Do they predict remaining lifespan better than chronological age?
- Issues: High biological noise, lack of standardization, false precision
- Movement age test gave Peter result of 22 years old at age 51 - clearly unrealistic
- Most tests haven't been validated against actual longevity outcomes
Energy and Aging Discussion
- Spontaneous energy outbursts decline dramatically from childhood to adulthood
- Unclear why energy decreases with age despite NAD supplementation
- Exercise timing matters: morning workouts (before 9am) provide all-day energy boost
- Late morning/afternoon workouts can be depleting for remainder of day
- Hypothesis: circadian temperature regulation interaction with exercise-induced temperature changes
Radiation Exposure Context
- Annual NRC recommendation: <50 millisieverts radiation exposure
- Sea level ambient: 1 mSv/year (2% of allowance)
- Colorado altitude: 2 mSv/year
- CT angiogram: 3-15 mSv depending on facility
- Nuclear plant workers: ~500 mSv/year with no increased cancer risk
- Airport scanners and flights: minimal concern based on pilot data
Critical Life Phases for Health Investment
- Ages 50-70 identified as crucial window for health span/lifespan optimization
- Aging effects become more apparent: reduced resilience, longer recovery times
- Goal: build maximum physiologic reserve while still possible
- Muscle mass addition becomes very difficult after mid-70s
- Power loss most dramatic (50% vertical jump decline from teens), followed by strength, then muscle mass
- Injury recovery ratios worsen: 2:1 or 3:1 inactivity to activity needed for recovery
Final Recommendations and Perspectives
Supplement Hierarchy (Titanic Analogy)
- Ship's direction (exercise, sleep, nutrition, emotional health) = primary determinants
- Supplement choices = "lobster vs steak" - secondary considerations
- All discussed supplements matter far less than foundational behaviors
NAD Pathway Verdict
- Peter: Does not take NR/NMN/NAD, sees no compelling evidence for longevity benefit
- Andrew: Takes NMN/NR but not for longevity - observes energy/hair growth effects
- Both agree: no evidence for lifespan extension, minimal evidence for health span benefits
- Potential exception: skin cancer prevention (requires replication)
Investment Philosophy
- Peter's conviction test: "Show me your portfolio, not your theories"
- Demonstrates conviction through actions: rigorous exercise, sleep optimization, selective supplementation
- Willing to change position based on new data
- Current assessment: NAD pathway supplementation not justified for longevity goals
